Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Giannicola Genovese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1392-9954; OpenAlex author ID A5046740782. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 5 papers

Papers 18

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  3. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  4. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-24-4211↗
  5. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  6. Switching on the evolutionary potential of pancreatic cancer: the tumor suppressor functions of PBRM1. First author DOI 10.1172/jci193205↗
  7. The KRAS mutational spectrum and its clinical implications in pancreatic cancer. First author DOI 10.1016/j.ccell.2024.08.001↗
  8. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Co-author DOI 10.1101/2024.10.21.619543↗
  9. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  10. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. First author DOI 10.3390/ijms24119313↗
  11. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  12. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  13. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
  14. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  15. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  16. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. First author DOI 10.1016/j.celrep.2016.05.063↗
  17. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  18. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giulio Francesco Draetta · 15 shared papers, 2014–2026 · strength 1.97
  2. Andrea Viale · 14 shared papers, 2014–2026 · strength 1.61
  3. Luigi Perelli · 5 shared papers, 2023–2026 · strength 1.42
  4. Huamin Wang · 11 shared papers, 2014–2026 · strength 1.26
  5. Haoqiang Ying · 11 shared papers, 2014–2026 · strength 1.26
  6. Alessandro Carugo · 11 shared papers, 2014–2026 · strength 1.14
  7. Timothy Paul Heffernan · 11 shared papers, 2014–2026 · strength 1.14
  8. Virginia Giuliani · 9 shared papers, 2014–2026 · strength 1.03
  9. Wantong Yao · 8 shared papers, 2014–2026 · strength 0.91
  10. Anirban Maitra · 9 shared papers, 2016–2026 · strength 0.90
  11. Jason B. Fleming · 9 shared papers, 2014–2026 · strength 0.87
  12. Ronald Anthony Depinho · 9 shared papers, 2014–2026 · strength 0.87
  13. I-Lin Ho · 5 shared papers, 2020–2026 · strength 0.74
  14. Francesca Citron · 4 shared papers, 2024–2026 · strength 0.66
  15. Ziheng Chen · 4 shared papers, 2024–2026 · strength 0.66
  16. Prasenjit Dey · 5 shared papers, 2017–2026 · strength 0.57
  17. Ya’an Kang · 5 shared papers, 2014–2026 · strength 0.53
  18. Tony Gutschner · 4 shared papers, 2017–2026 · strength 0.49
  19. Johnathon Lynn Rose · 4 shared papers, 2016–2026 · strength 0.41
  20. Piergiorgio Pettazzoni · 5 shared papers, 2014–2026 · strength 0.34
  21. Chiara Bonini · 2 shared papers, 2024–2026 · strength 0.31
  22. Michael P. Kim · 3 shared papers, 2020–2024 · strength 0.30
  23. Avnish Kapoor · 3 shared papers, 2014–2026 · strength 0.26
  24. Lynda Chin · 3 shared papers, 2016–2026 · strength 0.26
  25. Lifeng Yang · 2 shared papers, 2017–2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.